Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | COMBI-AD: QoL of patients

Georgina Long • 2 Jun 2019
ASCO 2019
Melanoma Skin Cancer Dabrafenib Trametinib
COMBI-AD

Georgina Long, MD, PhD, FRACP, of The University of Sydney, Sydney, Australia, discusses the quality of life of patients enrolled in the COMBI-AD trial. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Georgina Long

0:56
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab
Georgina Long • 10 Sep 2022
0:36
Challenges associated with implementing ctDNA approaches in melanoma
Georgina Long • 10 Sep 2022
2:01
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma
Georgina Long • 10 Sep 2022
1:20
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma
Georgina Long • 10 Sep 2022

Related Videos

1:48
Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma
Christoffer Gebhardt • 9 Apr 2024
1:56
Challenges and opportunities in TILs and TCR modified cell therapies
Sebastian Klobuch • 7 Apr 2024
0:55
The future role of lifileucel in melanoma
Sebastian Klobuch • 7 Apr 2024
1:29
Developments for TILs and TCR modified cell therapy in solid tumors
Sebastian Klobuch • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals